Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
ASX preview on Thursday: 8 shares you need to watch today
⏸️ Investing
Here's how much $5,000 invested on Monday in marijuana stock Stemcell Utd Ltd would be worth today
⏸️ Investing
REVEALED: 10 of the best ASX technology shares for 2017
⏸️ Investing
4 defensive shares I'd buy with $5,000 today
⏸️ Investing
3 ways you can profit from Australia's ageing population
⏸️ Investing
Your instant 5-share ASX healthcare portfolio
⏸️ Investing
PLUNGE: Australian dollar (A$) sheds 1%: What it means for you
⏸️ Investing
ASX preview on Thursday: 9 shares you need to watch today
⏸️ Investing
If the Australian Dollar (A$) plunges in 2017: Watch these 3 ASX shares
⏸️ Investing
RBA leaves rates on hold: 2 shares to profit from the changing rates outlook
⏸️ Investing
Here's how you can benefit from a weaker Australian Dollar (A$)
⏸️ Investing
Simple: 3 healthy ASX shares for 2027
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
